About Savara Inc.

Savara Inc., founded in 2007, is dedicated to developing innovative inhaled therapies for patients with severe rare respiratory diseases who have limited treatment options. The company's focus on pulmonary delivery enables targeted treatment with potentially reduced systemic side effects. SVRA stock price reflects both the significant medical need addressed by the company's programs and the inherent risks of rare disease drug development.

Led by CEO David Lowrance, Savara has advanced multiple programs through clinical trials while building capabilities in inhaled drug development and manufacturing. The management team combines expertise in pulmonary medicine with pharmaceutical development experience. Leadership's strategic focus on rare respiratory diseases and inhaled delivery has been important for differentiating the company's approach and influencing SVRA stock price trajectory.

Savara operates by developing inhaled therapies for rare lung diseases including nontuberculous mycobacterial (NTM) lung infection and autoimmune pulmonary alveolar proteinosis (aPAP). The company's pipeline includes novel formulations and delivery systems designed to improve treatment outcomes for patients with limited therapeutic options. With rare respiratory diseases representing significant unmet medical needs, potential for orphan drug designation and premium pricing, and Savara's specialized focus on pulmonary delivery, SVRA offers investors exposure to rare disease therapeutics with significant upside potential if clinical trials demonstrate efficacy in addressing conditions with few or no approved treatments.